Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan in High Risk Ewing's Sarcoma
NCT00276692Phase 2Completed
- Sponsor
- Children's Cancer and Leukaemia Group
- Start
- Aug 2003
- Primary completion
- Sep 2008
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of irinotecan in Ewing sarcoma, sponsored by Children's Cancer and Leukaemia Group. Primary endpoint: Response as measured by MRI. Started Aug 2003; status: completed.
02
Drugs
irinotecan
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on NCT00276692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00276692.